A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer.

@article{Geller2011API,
  title={A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer.},
  author={Melissa A. Geller and Sarah Cooley and Patricia L. Judson and Rahel Ghebre and Linda F. Carson and Peter A. Argenta and Amy L Jonson and Angela Panoskaltsis-Mortari and Julie M. Curtsinger and David McKenna and Kathryn Ellen Dusenbery and Robin L. Bliss and Levi S. Downs and Jeffrey S Miller},
  journal={Cytotherapy},
  year={2011},
  volume={13 1},
  pages={
          98-107
        }
}
BACKGROUND Natural killer (NK) cells derived from patients with cancer exhibit diminished cytotoxicity compared with NK cells from healthy individuals. We evaluated the tumor response and in vivo expansion of allogeneic NK cells in recurrent ovarian and breast cancer. METHODS Patients underwent a lymphodepleting preparative regimen: fludarabine 25 mg/m(2) × 5 doses, cyclophosphamide 60 mg/kg × 2 doses, and, in seven patients, 200 cGy total body irradiation (TBI) to increase host immune… CONTINUE READING
107 Citations
55 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 107 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 55 references

Rapamycin , unlike cyclosporine A , enhances suppressive functions of in vitroinduced CD 4  CD 25  Tregs

  • K Bocian, J Borysowski, P Wierzbicki, J Wyzgal, D Klosowska, A Bialoszewska
  • Nephrol Dial Transplant
  • 2009

Adoptively infused NK cells maintain their antitumor effects in vivo in the presence of cyclosporin A ( CSA )

  • H Yokoyama, A Lundqvist, M Berg, M Ramanathan, A Smith, N Gormley
  • Blood
  • 2008

Adoptively infused NK cells maintain their antitumor effects in vivo in the presence of cyclosporin A (CSA). Blood

  • A Smith, N Gormley
  • 2008

Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial

  • J Martinson
  • Cytotherapy
  • 2008

Successful haploidentical hematopoietic cell engraftment using a non-myeloablative preparative regimen including natural killer (NK) cells

  • M Verneris, BR Blazar
  • Blood
  • 2008

Similar Papers

Loading similar papers…